The National Authority for Health opinion relates to high-intensity focused ultrasound as a primary treatment for intermediate localized prostate cancer risk.
Owlstone Medical's Phase 2 clinical trial will assess the test's diagnostic performance and enable its optimization through testing protocol refinement.
Bladder EpiCheck it a sensitive, specific test to analyze subtle, disease-specific changes across 15 methylation markers associated with bladder cancer.
Study confirms that MESAs combined approach is superior at distinguishing between colon cancer patients and healthy individuals compared to other methods.